GNLX — GENELUX Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1231457 ·
Last close
$3.01
Market Cap
$134.97M
52W High
$3.25
52W Low
$2.29
ADV30
159,069
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,171,000 | -8,928,000 | 32,372,000 | 9,273,000 | 9,451,000 |
| Dec 2025 | 8,000 | — | -9,412,000 | -9,247,000 | 19,027,000 | 5,333,000 | 7,483,000 |
| Sep 2025 | 0 | — | -8,194,000 | -7,950,000 | 24,987,000 | 3,692,000 | 6,396,000 |
| Jun 2025 | 0 | — | -7,792,000 | -7,456,000 | 32,247,000 | 6,546,000 | 8,349,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,268,000
Investing CF
$12,141,000
Financing CF
$9,895,000
CapEx
$-1,098,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.81
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,538,000
Inventory
—
Receivables
—
ST Investments
$9,262,000
EBIT TTM
$-33,214,000
Pretax Income TTM
$-32,145,000
Interest Exp TTM
$0
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$8,000
EBITDA
$-34,375,000
Free Cash Flow
$-15,583,625
Enterprise Value
$107,220,016
Total Cash
$26,209,000
Total Debt
$2,495,000
Shares Out
44,840,416
Trailing EPS
$-0.85
Book Value
$0.52
ROE
-127.3%
ROA
-60.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,000 | -33,214,000 | -32,145,000 | 19,027,000 | 7,483,000 | — | -25,268,000 |
| Dec 2024 | 8,000 | -31,696,000 | -29,869,000 | 34,716,000 | 8,442,000 | — | -21,228,000 |
| Dec 2023 | 170,000 | -24,165,000 | -28,297,000 | 27,893,000 | 8,420,000 | — | -20,275,000 |
| Dec 2022 | 11,068,000 | -3,013,000 | -5,207,000 | 5,531,000 | 41,314,000 | — | -3,571,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.76
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CNTB | Connect Biopharma Holdings Ltd | $135.65M | $2.40 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $133.71M | $5.14 | — |
| DERM | Journey Medical Corp | $131.79M | $6.12 | — |
| VTVT | vTv Therapeutics Inc. | $130.61M | $33.16 | — |
| MSLE | Satellos Bioscience Inc. | $141.76M | $6.80 | — |
News headlines (Yahoo Finance, 1h cache)
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
2026-05-07 20:15 · Yahoo
Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
2026-03-19 20:15 · Yahoo
Genelux Corporation to Participate in Upcoming Conferences
2026-02-18 13:00 · Yahoo
Genelux Corporation Announces Upcoming Virtual Fireside Chat Hosted by Titan Partners
2026-01-12 21:00 · Yahoo
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock
2026-01-08 14:13 · Yahoo
Genelux Corporation Announces Proposed Public Offering of Common Stock
2026-01-07 21:01 · Yahoo
Genelux Corporation Reports Encouraging Interim Data of Systemic Administration of Olvi-Vec in Ongoing Lung Cancer Trials
2026-01-05 13:00 · Yahoo
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer
2026-01-02 13:00 · Yahoo
Genelux Corporation to Participate in a Fireside Chat at Piper Sandler 37th Annual Healthcare Conference
2025-11-26 13:00 · Yahoo
Institutions along with retail investors who hold considerable shares inGenelux Corporation (NASDAQ:GNLX) come under pressure; lose 16% of holdings value
2025-11-20 10:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.